Microbial Modulation in Inflammatory Bowel Diseases

키워드

참고문헌 (170)

1. Jihye Park, "Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α", The Korean Journal of Internal Medicine, 37(5), pp.895~905 (2022), 대한내과학회[DOI]
2. 박지혜, "Incidence and Prevalence of Inflammatory Bowel Disease across Asia", Yonsei Medical Journal, 62(2), pp.99~108 (2021), 연세대학교의과대학[DOI]
3. 박상형, "Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?", Intestinal research, 20(2), pp.159~164 (2022), 대한장연구학회[DOI]
4. Chang JT, "Pathophysiology of inflammatory bowel diseases", N Engl J Med, 383, pp.2652~2664 (2020)
5. Knox NC, "The gut microbiome in inflammatory bowel disease : lessons learned from other immune-mediated inflammatory diseases", Am J Gastroenterol, 114, pp.1051~1070 (2019)
6. Kanika Sehgal, "Gut microbiome and checkpoint inhibitor colitis", Intestinal research, 19(4), pp.360~364 (2021), 대한장연구학회[DOI]
7. Dave M, "The human gut microbiome : current knowledge, challenges, and future directions", Transl Res, 160, pp.246~257 (2012)
8. Lloyd-Price J, "The healthy human microbiome", Genome Med, 8, pp.51~ (2016)
9. 신승용, "Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease", Intestinal research, 21(1), pp.148~160 (2023), 대한장연구학회[DOI]
10. Shigeki Bamba, "Relationship between the gut microbiota and bile acid composition in the ileal mucosa of Crohn’s disease", Intestinal research, 20(3), pp.370~380 (2022), 대한장연구학회[DOI]
11. de Lange KM, "Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease", Nat Genet, 49, pp.256~261 (2017)
12. Levy M, "Dysbiosis and the immune system", Nat Rev Immunol, 17, pp.219~232 (2017)
13. Gevers D, "The treatment-naive microbiome in new-onset Crohn’s disease", Cell Host Microbe, 15, pp.382~392 (2014)
14. Human Microbiome Project Consortium, "Structure, function and diversity of the healthy human microbiome", Nature, 486, pp.207~214 (2012)
15. Kao D, "Fecal microbiota transplantation inducing remission in Crohn’s colitis and the associated changes in fecal microbial profile", J Clin Gastroenterol, 48, pp.625~628 (2014)
16. Ni J, "Gut microbiota and IBD : causation or correlation?", Nat Rev Gastroenterol Hepatol, 14, pp.573~584 (2017)
17. Seksik P, "Review article : the role of bacteria in onset and perpetuation of inflammatory bowel disease", Aliment Pharmacol Ther, 24(Suppl 3), pp.11~18 (2006)
18. Manichanh C, "The gut microbiota in IBD", Nat Rev Gastroenterol Hepatol, 9, pp.599~608 (2012)
19. Kim S, "The intestinal microbiota : antibiotics, colonization resistance, and enteric pathogens", Immunol Rev, 279, pp.90~105 (2017)
20. Cai R, "Interactions of commensal and pathogenic microorganisms with the mucus layer in the colon", Gut Microbes, 11, pp.680~690 (2020)
21. Campieri M, "Bacteria as the cause of ulcerative colitis", Gut, 48, pp.132~135 (2001)
22. Mirsepasi-Lauridsen HC, "Secretion of alpha-hemolysin by escherichia coli disrupts tight junctions in ulcerative colitis patients", Clin Transl Gastroenterol, 7, pp.e149~ (2016)
23. Kim SC, "Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria", Gastroenterology, 128, pp.891~906 (2005)
24. Gradel KO, "Increased short-and longterm risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis", Gastroenterology, 137, pp.495~501 (2009)
25. García Rodríguez LA, "Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease", Gastroenterology, 130, pp.1588~1594 (2006)
26. Porter CK, "Infectious gastroenteritis and risk of developing inflammatory bowel disease", Gastroenterology, 135, pp.781~786 (2008)
27. Docktor MJ, "Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease", Inflamm Bowel Dis, 18, pp.935~942 (2012)
28. Frank DN, "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases", Proc Natl Acad Sci U S A, 104, pp.13780~13785 (2007)
29. Clooney AG, "Ranking microbiome variance in inflammatory bowel disease : a large longitudinal intercontinental study", Gut, 70, pp.499~510 (2021)
30. Bellaguarda E, "IBD and the gut microbiota--from bench to personalized medicine", Curr Gastroenterol Rep, 17, pp.15~ (2015)
31. Walker AW, "High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease", BMC Microbiol, 11, pp.7~ (2011)
32. Kostic AD, "The microbiome in inflammatory bowel disease : current status and the future ahead", Gastroenterology, 146, pp.1489~1499 (2014)
33. Sokol H, "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", Proc Natl Acad Sci U S A, 105, pp.16731~16736 (2008)
34. Morgan XC, "Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment", Genome Biol, 13, pp.R79~ (2012)
35. Manichanh C, "Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach", Gut, 55, pp.205~211 (2006)
36. Martín R, "The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models", Inflamm Bowel Dis, 20, pp.417~430 (2014)
37. Lopez-Siles M, "Faecalibacterium prausnitzii : from microbiology to diagnostics and prognostics", ISME J, 11, pp.841~852 (2017)
38. Rehman A, "Geographical patterns of the standing and active human gut microbiome in health and IBD", Gut, 65, pp.238~248 (2016)
39. 김덕환, "Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies", Immune Network, 17(1), pp.25~40 (2017), 대한면역학회[DOI]
40. Basson A, "Mucosal interactions between genetics, diet, and microbiome in inflammatory bowel disease", Front Immunol, 7, pp.290~ (2016)
41. Kamada N, "Role of the gut microbiota in immunity and inflammatory disease", Nat Rev Immunol, 13, pp.321~335 (2013)
42. 박이슬, "Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice", Intestinal research, 19(3), pp.349~353 (2021), 대한장연구학회[DOI]
43. Blander JM, "Regulation of inflammation by microbiota interactions with the host", Nat Immunol, 18, pp.851~860 (2017)
44. Li E, "Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition", PLoS One, 7, pp.e26284~ (2012)
45. Kamada N, "Role of the gut microbiota in the development and function of lymphoid cells", J Immunol, 190, pp.1389~1395 (2013)
46. Chang PV, "The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition", Proc Natl Acad Sci U S A, 111, pp.2247~2252 (2014)
47. Ananthakrishnan AN, "Microbiome-based biomarkers for IBD", Inflamm Bowel Dis, 26, pp.1463~1469 (2020)
48. Park YE, "Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases", Sci Rep, 12, pp.6359~ (2022)
49. Knox NC, "The gut microbiome as a target for IBD treatment : are we there yet?", Curr Treat Options Gastroenterol, 17, pp.115~126 (2019)
50. 윤미영, "Disruption of the Gut Ecosystem by Antibiotics", Yonsei Medical Journal, 59(1), pp.4~12 (2018), 연세대학교의과대학[DOI]
51. Dethlefsen L, "The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing", PLoS Biol, 6, pp.e280~ (2008)
52. Antonopoulos DA, "Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation", Infect Immun, 77, pp.2367~2375 (2009)
53. Manichanh C, "Reshaping the gut microbiome with bacterial transplantation and antibiotic intake", Genome Res, 20, pp.1411~1419 (2010)
54. Dethlefsen L, "Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation", Proc Natl Acad Sci U S A, 108(Suppl 1), pp.4554~4561 (2011)
55. Cho I, "Antibiotics in early life alter the murine colonic microbiome and adiposity", Nature, 488, pp.621~626 (2012)
56. Poo S, "Network meta-analysis : efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis", Eur J Gastroenterol Hepatol, 34, pp.518~528 (2022)
57. Relman DA, "The human microbiome : ecosystem resilience and health", Nutr Rev, 70(Suppl 1), pp.S2~S9 (2012)
58. Jernberg C, "Long-term ecological impacts of antibiotic administration on the human intestinal microbiota", ISME J, 1, pp.56~66 (2007)
59. Jernberg C, "Long-term impacts of antibiotic exposure on the human intestinal microbiota", Microbiology, 156, pp.3216~3223 (2010)
60. Hviid A, "Antibiotic use and inflammatory bowel diseases in childhood", Gut, 60, pp.49~54 (2011)
61. Shaw SY, "Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease", Am J Gastroenterol, 105, pp.2687~2692 (2010)
62. Nguyen LH, "Antibiotic use and the development of inflammatory bowel disease : a national case-control study in Sweden", Lancet Gastroenterol Hepatol, 5, pp.986~995 (2020)
63. Khan KJ, "Antibiotic therapy in inflammatory bowel disease : a systematic review and meta-analysis", Am J Gastroenterol, 106, pp.661~673 (2011)
64. Segal JP, "Systematic review with meta-analysis : the management of chronic refractory pouchitis with an evidence-based treatment algorithm", Aliment Pharmacol Ther, 45, pp.581~592 (2017)
65. Nguyen N, "Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis", Cochrane Database Syst Rev, 11, pp.CD001176~ (2019)
66. Xi W, "Effect of antibiotic therapy in patients with ulcerative colitis : a meta-analysis of randomized controlled trials", Scand J Gastroenterol, 56, pp.162~170 (2021)
67. Gordon M, "Antibiotics for the induction and maintenance of remission in ulcerative colitis", Cochrane Database Syst Rev, 5, pp.CD013743~ (2022)
68. Townsend CM, "Antibiotics for induction and maintenance of remission in Crohn’s disease", Cochrane Database Syst Rev, 2, pp.CD012730~ (2019)
69. Borgaonkar MR, "A meta-analysis of antimycobacterial therapy for Crohn’s disease", Am J Gastroenterol, 95, pp.725~729 (2000)
70. Patton PH, "Anti-tuberculous therapy for maintenance of remission in Crohn’s disease", Cochrane Database Syst Rev, 7, pp.CD000299~ (2016)
71. Feller M, "Mycobacterium avium subspecies paratuberculosis and Crohn’s disease : a systematic review and meta-analysis", Lancet Infect Dis, 7, pp.607~613 (2007)
72. Prantera C, "Antibiotic treatment of Crohn’s disease : results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin", Aliment Pharmacol Ther, 23, pp.1117~1125 (2006)
73. Nitzan O, "Role of antibiotics for treatment of inflammatory bowel disease", World J Gastroenterol, 22, pp.1078~1087 (2016)
74. Ekmekciu I, "Immune responses to broad-spectrum antibiotic treatment and fecal microbiota transplantation in mice", Front Immunol, 8, pp.397~ (2017)
75. Schrezenmeir J, "Probiotics, prebiotics, and synbiotics--approaching a definition", Am J Clin Nutr, 73(Suppl), pp.361~ (2001)
76. Su GL, "AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders", Gastroenterology, 159, pp.697~705 (2020)
77. Emiko Mizoguchi, "Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models", Intestinal research, 18(2), pp.151~167 (2020), 대한장연구학회[DOI]
78. Eisenhauer N, "Bacterial diversity stabilizes community productivity", PLoS One, 7, pp.e34517~ (2012)
79. Zmora N, "Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features", Cell, 174, pp.1388~1405 (2018)
80. Cox MJ, "Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome", PLoS One, 5, pp.e8745~ (2010)
81. Tannock GW, "Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20", Appl Environ Microbiol, 66, pp.2578~2588 (2000)
82. Dotterud CK, "Does maternal perinatal probiotic supplementation alter the intestinal microbiota of mother and child?", J Pediatr Gastroenterol Nutr, 61, pp.200~207 (2015)
83. Maldonado-Gómez MX, "Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome", Cell Host Microbe, 20, pp.515~526 (2016)
84. Barathikannan K, "Gut microbiome modulation based on probiotic application for anti-obesity : a review on efficacy and validation", Microorganisms, 7, pp.7~ (2019)
85. Ki Cha B, "The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome : a randomized, double-blind, placebo-controlled trial", J Clin Gastroenterol, 46, pp.220~227 (2012)
86. Guyonnet D, "Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care : a multicentre, randomized, doubleblind, controlled trial", Aliment Pharmacol Ther, 26, pp.475~486 (2007)
87. Larsen N, "Predominant genera of fecal microbiota in children with atopic dermatitis are not altered by intake of probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07", FEMS Microbiol Ecol, 75, pp.482~496 (2011)
88. Veiga P, "Changes of the human gut microbiome induced by a fermented milk product", Sci Rep, 4, pp.6328~ (2014)
89. Zheng D, "Interaction between microbiota and immunity in health and disease", Cell Res, 30, pp.492~506 (2020)
90. Wieërs G, "How probiotics affect the microbiota", Front Cell Infect Microbiol, 9, pp.454~ (2020)
91. Satokari R, "Modulation of gut microbiota for health by current and next-generation probiotics", Nutrients, 11, pp.11~ (2019)
92. Hart AL, "Use of probiotics in the treatment of inflammatory bowel disease", J Clin Gastroenterol, 36, pp.111~119 (2003)
93. Kruis W, "Antibiotics and probiotics in inflammatory bowel disease", Aliment Pharmacol Ther, 20(Suppl 4), pp.75~78 (2004)
94. Derwa Y, "Systematic review with meta-analysis : the efficacy of probiotics in inflammatory bowel disease", Aliment Pharmacol Ther, 46, pp.389~400 (2017)
95. Wasilewski A, "Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease", Inflamm Bowel Dis, 21, pp.1674~1682 (2015)
96. Liu Q, "Surface components and metabolites of probiotics for regulation of intestinal epithelial barrier", Microb Cell Fact, 19, pp.23~ (2020)
97. 박지혜, "Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model", Intestinal research, 19(4), pp.478~481 (2021), 대한장연구학회[DOI]
98. Jonkers D, "Probiotics in the management of inflammatory bowel disease : a systematic review of intervention studies in adult patients", Drugs, 72, pp.803~823 (2012)
99. Shen J, "Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis : meta-analysis of randomized controlled trials", Inflamm Bowel Dis, 20, pp.21~35 (2014)
100. Ganji-Arjenaki M, "Probiotics are a good choice in remission of inflammatory bowel diseases : a meta analysis and systematic review", J Cell Physiol, 233, pp.2091~2103 (2018)
101. Zhang XF, "Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease : a systematic review and meta-analysis", Eur J Nutr, 60, pp.2855~2875 (2021)
102. Astó E, "The efficacy of probiotics, prebiotic inulintype fructans, and synbiotics in human ulcerative colitis : a systematic review and meta-analysis", Nutrients, 11, pp.11~ (2019)
103. Chen MY, "Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: a systematic review and metaanalysis", Medicine(Baltimore), 98, pp.e17955~ (2019)
104. Iheozor-Ejiofor Z, "Probiotics for maintenance of remission in ulcerative colitis", Cochrane Database Syst Rev, 3, pp.CD007443~ (2020)
105. Kaur L, "Probiotics for induction of remission in ulcerative colitis", Cochrane Database Syst Rev, 3, pp.CD005573~ (2020)
106. Limketkai BN, "Probiotics for induction of remission in Crohn’s disease", Cochrane Database Syst Rev, 7, pp.CD006634~ (2020)
107. Lane ER, "The microbiota in inflammatory bowel disease : current and therapeutic insights", J Inflamm Res, 10, pp.63~73 (2017)
108. Orel R, "Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease", World J Gastroenterol, 20, pp.11505~11524 (2014)
109. White R, "Randomized, controlled trial evaluating the effect of multi-strain probiotic on the mucosal microbiota in canine idiopathic inflammatory bowel disease", Gut Microbes, 8, pp.451~466 (2017)
110. Tojo R, "Intestinal microbiota in health and disease : role of bifidobacteria in gut homeostasis", World J Gastroenterol, 20, pp.15163~15176 (2014)
111. Mack DR, "Probiotics in inflammatory bowel diseases and associated conditions", Nutrients, 3, pp.245~264 (2011)
112. Hemarajata P, "Effects of probiotics on gut microbiota : mechanisms of intestinal immunomodulation and neuromodulation", Therap Adv Gastroenterol, 6, pp.39~51 (2013)
113. Preidis GA, "Probiotics stimulate enterocyte migration and microbial diversity in the neonatal mouse intestine", FASEB J, 26, pp.1960~1969 (2012)
114. Su H, "Effects of glucocorticoids combined with probiotics in treating Crohn’s disease on inflammatory factors and intestinal microflora", Exp Ther Med, 16, pp.2999~3003 (2018)
115. Matsuoka K, "Efficacy of bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis", Dig Dis Sci, 63, pp.1910~1919 (2018)
116. Kato K, "Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis", Aliment Pharmacol Ther, 20, pp.1133~1141 (2004)
117. Ishikawa H, "Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis : a randomized controlled study", Digestion, 84, pp.128~133 (2011)
118. Cui HH, "Effects of probiotic on intestinal mucosa of patients with ulcerative colitis", World J Gastroenterol, 10, pp.1521~1525 (2004)
119. Rehman A, "Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine", BMC Microbiol, 12, pp.47~ (2012)
120. Suez J, "Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT", Cell, 174, pp.1406~1423 (2018)
121. Thomas CM, "Probiotics-host communication : modulation of signaling pathways in the intestine", Gut Microbes, 1, pp.148~163 (2010)
122. Gewirtz AT, "Cutting edge : bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression", J Immunol, 167, pp.1882~1885 (2001)
123. O’Connell Motherway M, "A Bifidobacterial pilus-associated protein promotes colonic epithelial proliferation", Mol Microbiol, 111, pp.287~301 (2019)
124. Porter NT, "A subset of polysaccharide capsules in the human symbiont Bacteroides thetaiotaomicron promote increased competitive fitness in the mouse gut", Cell Host Microbe, 22, pp.494~506 (2017)
125. Gibson GR, "Expert consensus document : The International Scientific Association for Probiotics and Prebiotics(ISAPP)consensus statement on the definition and scope of prebiotics", Nat Rev Gastroenterol Hepatol, 14, pp.491~502 (2017)
126. Lindsay JO, "Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease", Gut, 55, pp.348~355 (2006)
127. Benjamin JL, "Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease", Gut, 60, pp.923~929 (2011)
128. Hafer A, "Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease : a pilot study", BMC Gastroenterol, 7, pp.36~ (2007)
129. Casellas F, "Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin", Aliment Pharmacol Ther, 25, pp.1061~1067 (2007)
130. Kao D, "Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection : a randomized clinical trial", JAMA, 318, pp.1985~1993 (2017)
131. Ooijevaar RE, "Clinical application and potential of fecal microbiota transplantation", Annu Rev Med, 70, pp.335~351 (2019)
132. Sahil Khanna, "Management of Clostridioides difficile infection in patients with inflammatory bowel disease", Intestinal research, 19(3), pp.265~274 (2021), 대한장연구학회[DOI]
133. Le Bastard Q, "Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut dysbiosis in mice", Sci Rep, 8, pp.6219~ (2018)
134. Anderson JL, "Systematic review : faecal microbiota transplantation in the management of inflammatory bowel disease", Aliment Pharmacol Ther, 36, pp.503~516 (2012)
135. Colman RJ, "Fecal microbiota transplantation as therapy for inflammatory bowel disease : a systematic review and meta-analysis", J Crohn’s Colitis, 8, pp.1569~1581 (2014)
136. Sha S, "Systematic review : faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children", Aliment Pharmacol Ther, 39, pp.1003~1032 (2014)
137. Lai CY, "Systematic review with meta-analysis : review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation", Aliment Pharmacol Ther, 49, pp.354~363 (2019)
138. Chen T, "Effect of faecal microbiota transplantation for treatment of clostridium difficile infection in patients with inflammatory bowel disease : a systematic review and meta-analysis of cohort studies", J Crohn’s Colitis, 12, pp.710~717 (2018)
139. Tariq R, "Outcomes of fecal microbiota transplantation for C. difficile infection in inflammatory bowel disease: a systematic review and meta-analysis", J Clin Gastroenterol (2021)[DOI]
140. Paramsothy S, "Faecal microbiota transplantation for inflammatory bowel disease : a systematic review and meta-analysis", J Crohn’s Colitis, 11, pp.1180~1199 (2017)
141. Qazi T, "The risk of inflammatory bowel disease flares after fecal microbiota transplantation : Systematic review and meta-analysis", Gut Microbes, 8, pp.574~588 (2017)
142. Imdad A, "Fecal transplantation for treatment of inflammatory bowel disease", Cochrane Database Syst Rev, 11, pp.CD012774~ (2018)
143. Fehily SR, "Fecal microbiota transplantation therapy in Crohn’s disease : systematic review", J Gastroenterol Hepatol, 36, pp.2672~2686 (2021)
144. Lee MJ, "Efficacy of medical therapies for fistulizing Crohn’s disease : systematic review and meta-analysis", Clin Gastroenterol Hepatol, 16, pp.1879~1892 (2018)
145. Narula N, "Systematic review and meta-analysis : fecal microbiota transplantation for treatment of active ulcerative colitis", Inflamm Bowel Dis, 23, pp.1702~1709 (2017)
146. Costello SP, "Systematic review with meta-analysis : faecal microbiota transplantation for the induction of remission for active ulcerative colitis", Aliment Pharmacol Ther, 46, pp.213~224 (2017)
147. Green JE, "Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection : a systematic review and meta-analysis", Gut Microbes, 12, pp.1~25 (2020)
148. Angelberger S, "Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation", Am J Gastroenterol, 108, pp.1620~1630 (2013)
149. Kump PK, "Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis", Inflamm Bowel Dis, 19, pp.2155~2165 (2013)
150. Rossen NG, "Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis", Gastroenterology, 149, pp.110~118 (2015)
151. Fuentes S, "Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation", ISME J, 11, pp.1877~1889 (2017)
152. Paramsothy S, "Multidonor intensive faecal microbiota transplantation for active ulcerative colitis : a randomised placebo-controlled trial", Lancet, 389, pp.1218~1228 (2017)
153. Zuo T, "Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection", Nat Commun, 9, pp.3663~ (2018)
154. Xiao Y, "An ecological framework to understand the efficacy of fecal microbiota transplantation", Nat Commun, 11, pp.3329~ (2020)
155. Zeng W, "Cutting edge : probiotics and fecal microbiota transplantation in immunomodulation", J Immunol Res, 2019, pp.1603758~ (2019)
156. Tan P, "Fecal microbiota transplantation for the treatment of inflammatory bowel disease : an update", Front Pharmacol, 11, pp.574533~ (2020)
157. Ianiro G, "Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases", Nat Med, 28, pp.1913~1923 (2022)
158. Burrello C, "Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells", Nat Commun, 9, pp.5184~ (2018)
159. Littmann ER, "Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection", Nat Commun, 12, pp.755~ (2021)
160. Britton GJ, "Defined microbiota transplant restores Th17", RORγt+ regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas, 2020, pp.117, 21536~21545
161. Salminen S, "The International Scientific Association of Probiotics and Prebiotics(ISAPP)consensus statement on the definition and scope of postbiotics", Nat Rev Gastroenterol Hepatol, 18, pp.649~667 (2021)
162. Wong AC, "New approaches to microbiome-based therapies", mSystems, 4, pp.e00122-19~ (2019)
163. Tsilingiri K, "Probiotic and postbiotic activity in health and disease : comparison on a novel polarised ex-vivo organ culture model", Gut, 61, pp.1007~1015 (2012)
164. Russo E, "Immunomodulating activity and therapeutic effects of short chain fatty acids and tryptophan post-biotics in inflammatory bowel disease", Front Immunol, 10, pp.2754~ (2019)
165. Markowiak-Kopeć P, "The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome", Nutrients, 12, pp.12~ (2020)
166. Wegh CA, "Postbiotics and their potential applications in early life nutrition and beyond", Int J Mol Sci, 20, pp.20~ (2019)
167. Kim DH, "An Escherichia coli strain with extra catalase activity protects against murine colitis by scavenging hydrogen peroxide and regulating regulatory t cell", interleukin-17 pathways, 2021, pp.174, 110~120
168. Yoon MY, "A single gene of a commensal microbe affects host susceptibility to enteric infection", Nat Commun, 7, pp.11606~ (2016)
169. Mauras A, "A new Bifidobacteria Expression SysTem(BEST)to produce and deliver interleukin-10 in Bifidobacterium bifidum", Front Microbiol, 9, pp.3075~ (2018)
170. Hong N, "Production of biologically active human interleukin-10 by Bifidobacterium bifidum BGN4", Microb Cell Fact, 20, pp.16~ (2021)

관련 논문AI추천